NorthStrive Biosciences Ships EL-32 Cell Bank, Launches Manufacturing Optimization Program
NorthStrive Biosciences transferred its EL-32 Working Cell Bank to a U.S.-based fermentation facility and launched a manufacturing optimization program to boost production yields and scalability for dual-action probiotic targeting myostatin and activin-A pathways. Collaboration with Modulant Biosciences aims to support IND-enabling activities and future GMP-compliant manufacturing.
1. Working Cell Bank Transfer
NorthStrive moved its EL-32 Working Cell Bank to a U.S. precision fermentation facility, launching an optimization program aimed at enhancing upstream and downstream processes to increase yield and drive cost-effective, scalable manufacturing.
2. EL-32 Therapeutic Profile
EL-32 is a dual-action engineered probiotic designed to express myostatin and activin-A antigens, offering an oral delivery approach to preserve lean muscle mass and address metabolic dysfunction in patients on GLP-1 receptor agonists.
3. Collaboration with Modulant Biosciences
Modulant Biosciences manages upstream and downstream process development under an exclusive animal health license, while NorthStrive retains human therapeutic rights, enabling parallel development and shared manufacturing insights.
4. Development and Commercial Outlook
The optimization program supports future IND-enabling studies and GMP manufacturing, positioning EL-32 for clinical readiness in human therapeutics and commercial animal health applications.